NANOMICRO(688690)2024-04-24 10:52Financial Performance - The company's operating revenue for 2023 was CNY 58,686.51 million, a decrease of 16.86% compared to CNY 70,584.12 million in 2022[21]. - The net profit attributable to shareholders for 2023 was CNY 6,856.63 million, down 75.08% from CNY 27,512.76 million in 2022[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 3,158.65 million, a decline of 83.97% from CNY 19,704.99 million in 2022[21]. - The net cash flow from operating activities for 2023 was CNY 12,553.05 million, an increase of 12.19% from CNY 11,188.81 million in 2022[21]. - The gross profit margin for 2023 was 78.07%, remaining stable compared to the previous year[141]. - The company reported a total revenue of 587 million, a decrease of 16.86% compared to the previous year, with a 7.59% decline when excluding the impact of nucleic acid testing products from the prior year[141]. - The net profit attributable to shareholders was 68.57 million yuan, down 75.08% year-on-year, while the net profit excluding non-recurring gains and losses was 31.59 million yuan, a decrease of 83.97%[23]. Dividend Distribution - The proposed profit distribution plan for 2023 is to distribute a cash dividend of 0.50 CNY per 10 shares, totaling approximately 20,066,317.55 CNY, which accounts for 29.27% of the net profit attributable to shareholders[6]. - The company is committed to maintaining the proportion of dividend distribution even if the number of shares changes before the dividend record date[6]. Audit and Compliance - The board of directors and supervisory board have confirmed the authenticity and completeness of the annual report[5]. - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[6]. - The company has not reported any instances where more than half of the directors could not guarantee the authenticity of the annual report[9]. - The company has not violated any decision-making procedures for providing guarantees[9]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. Research and Development - The company’s R&D expenditure accounted for 27.54% of operating revenue, an increase of 10.95 percentage points from the previous year[22]. - The total R&D expenses for the year amounted to 161.64 million yuan, representing a significant increase of 38.07% compared to the same period last year, with a 25.84% increase when excluding share-based payment expenses[93]. - The number of R&D personnel increased to 210, accounting for 27.45% of the total workforce, up from 25.73% in the previous period[102]. - The company has applied for 33 new intellectual property rights during the reporting period, with 21 granted, bringing the total to 225 applications and 115 grants[90][91]. Market and Product Development - The company plans to enhance its market expansion and product promotion efforts while increasing R&D investments to build long-term competitive advantages[23]. - The company is focused on domestic and international market expansion, aiming to break the long-standing technology and product monopoly of foreign companies in the high-performance microsphere market[53]. - The company has developed a comprehensive range of chromatographic media, including silica gel and polymer-based products, to meet diverse customer needs[105]. - The company has launched several new chromatography columns and sample pre-treatment products, achieving domestic production capabilities[97]. Risk Management - The company has outlined various risks and countermeasures in the management discussion and analysis section of the report[5]. - The company faces risks related to the potential theft or replication of its proprietary technologies, which could undermine its competitive edge in the chromatography medium industry[115]. - The company is exposed to risks from intensified market competition, particularly from large multinational corporations that dominate the chromatography medium supply[119]. Strategic Acquisitions - The company announced plans to acquire a total of 44.80% equity in Zhejiang Fuli Analytical Instrument Co., Ltd. through cash transactions, pending regulatory approvals[48]. - The company completed the first acquisition of 18.1999% equity in Zhejiang Fuli Analytical Instrument Co., Ltd. for a total investment of RMB 179.2 million, holding a 44.8% stake[174]. Inventory and Accounts Management - Inventory at the end of the reporting period was valued at 272.18 million yuan, representing 12.80% of total assets, indicating a high inventory level[123]. - The company recognized inventory impairment losses of 12.11 million yuan in 2023, an increase of 9.15 million yuan compared to the previous year[123]. - The company plans to enhance its credit management policies and improve inventory management through ERP systems to optimize operational efficiency[124]. Future Outlook - The company aims for over 50% year-on-year growth in sales revenue from chromatography fillers in key application areas such as ADC, GLP-1, and blood products in 2024[186]. - The company plans to maintain R&D investment at over 15% of revenue in 2024, with plans to launch multiple innovative products including new Protein A affinity chromatography media and hybrid silica chromatography fillers[188]. - The company is committed to optimizing internal control mechanisms to enhance risk management and operational efficiency[189].